Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02363868
What this trial is testing

Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Who this might be right for
Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb 186
Testing effectiveness (Phase 2)UnknownNCT01168050
What this trial is testing

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Who this might be right for
Malignant Skin Melanoma T0Stage III MelanomaStage IV Melanoma+1 more
Assistance Publique - Hôpitaux de Paris 25
Testing effectiveness (Phase 2)Ended earlyNCT02374489
What this trial is testing

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma
National Health Research Institutes, Taiwan 9
Testing effectiveness (Phase 2)Study completedNCT00006104
What this trial is testing

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 46
Not applicableLooking for participantsNCT07510724
What this trial is testing

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

Who this might be right for
Small Cell Lung Cancer (SCLC)Non-Small Cell Lung Cancer (NSCLC)Lung Cancer (Diagnosis)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 240
Testing effectiveness (Phase 2)Study completedNCT00059722
What this trial is testing

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Genzyme, a Sanofi Company 160
Testing effectiveness (Phase 2)Ended earlyNCT00681876
What this trial is testing

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hellenic Oncology Research Group 16
Testing effectiveness (Phase 2)Ended earlyNCT01994213
What this trial is testing

Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 53
Large-scale testing (Phase 3)UnknownNCT00465491
What this trial is testing

Study of Picoplatin Efficacy After Relapse

Who this might be right for
Small Cell Lung Cancer
Poniard Pharmaceuticals 399
Testing effectiveness (Phase 2)Study completedNCT00044343
What this trial is testing

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Who this might be right for
Colorectal Cancer
GlaxoSmithKline 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07347444
What this trial is testing

Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

Who this might be right for
Acral MelanomaMucosal Melanoma
Fudan University 48
Post-approval studies (Phase 4)Study completedNCT01066884
What this trial is testing

First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 5
Testing effectiveness (Phase 2)Study completedNCT01860638
What this trial is testing

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Who this might be right for
Glioblastoma
Hoffmann-La Roche 296
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Large-scale testing (Phase 3)Study completedNCT00805194
What this trial is testing

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,314
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Large-scale testing (Phase 3)Temporarily pausedNCT02037529
What this trial is testing

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2/Neu NegativeInvasive Breast Carcinoma+2 more
Academic and Community Cancer Research United 201
Not applicableUnknownNCT00400907
What this trial is testing

Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9

Who this might be right for
Long-term Effects Secondary to Cancer Therapy in AdultsLymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 667
Not applicableStudy completedNCT02551263
What this trial is testing

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 201
Early research (Phase 1)Study completedNCT01189942
What this trial is testing

FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
OncoMed Pharmaceuticals, Inc. 18
Next Page